Insider filing
Traded Sep 1 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 10, 2026 · Filed Aug 13, 2026
Corcept Therapeutics's Chief Development Officer sold $1.3M of Corcept Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,304,933
Shares × reported transaction price
12 days after results of Jul 29, 2026, 85 days before results of Nov 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $114.23 on Aug 10, 2026, within 4% of its 52-week high, after a 31% rise over the previous 30 trading days
52-week range $32.15 (Mar 13, 2026) to $118.32 (Jul 30, 2026), 95% of the way up, from 251 adjusted closes. 30 trading days earlier: $87.32 on Jun 26, 2026. Describes the past only, not a forecast
RSI 67, 82% above its 200-day average, 28% above its 50-day average, 3% below the 52-week high, 20-day volatility 99% a year, against the S&P 500: +22 points over 1 month, +114 points over 3 months, +168 points over 6 months
From the adjusted closes up to Aug 10, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +9.5% | −2.0% | +11.5% |
| 30 days | +1.2% | −2.2% | +3.4% |
| 90 days | −32.6% | −2.3% | −30.2% |
Past results only. Not a forecast.
Insider filing
Traded Sep 1 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Sep 1 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Sep 1 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.